[Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy].

Abstract

Prednisone monotherapy is the treatment of choice for patients with a nephrotic syndrome due to minimal change glomerulopathy. In adult patients treatment should be continued for at least 24 weeks. Within this period a remission of proteinuria will occur in 75 to 90% of the patients. Patients who do not respond satisfactorily to prednisone treatment can be treated with alkylating agents. Cyclophosphamide is the drug used most commonly. Prolonged treatment (> 12 weeks) is associated with a high risk of infertility. If alkylating agents cannot be used, prolonged treatment with ciclosporine is an option.

• Authors: A J Branten, J F Wetzels
• Journal: Nederlands tijdschrift voor geneeskunde (Ned Tijdschr Geneeskd) Vol. 142 Issue 52 Pg. 2832-8 (Dec 26 1998) ISSN: 0028-2162 [Print] Netherlands
• Vernacular Title: Immunosuppressieve behandeling van patiënten met een nefrotisch syndroom op basis van 'minimal-change'-glomerulopathie.
• PMID: 10065257 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Adrenal Cortex Hormones
• Angiotensin-Converting Enzyme Inhibitors
• Anti-Inflammatory Agents
• Anticoagulants
• Immunosuppressive Agents
• Prednisone

Topics

• Adolescent
• Adrenal Cortex Hormones (therapeutic use)
• Adult
• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Anti-Inflammatory Agents (therapeutic use)
• Anticoagulants (therapeutic use)
• Biopsy
• Child
• Child, Preschool
• Diagnosis, Differential
• Female
• Glomerular Filtration Rate (drug effects)
• Humans
• Hypertension (drug therapy, etiology)
• Immunosuppressive Agents (therapeutic use)
• Kidney (pathology)
• Male
• Nephrosis, Lipoid (complications, diagnosis, drug therapy)
• Nephrotic Syndrome (diagnosis, drug therapy, etiology)
• Prednisone (therapeutic use)
• Proteinuria (drug therapy, etiology)
• Remission Induction